2026-06-17

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Phase 3 trial terminated early — JOHNSON The Duration Study

Phase 3 trial terminated early — JOHNSON MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Au

Phase 3 trial terminated early — JOHNSON Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Phase 3 trial terminated early — ELI Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adul

Phase 3 trial terminated early — BRISTOL A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone i

Phase 3 trial terminated early — BRISTOL Apixaban in Patients With Sickle Cell Disease

Phase 3 trial terminated early — BIOGEN A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progressi

Phase 3 trial terminated early — BIOGEN Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

Phase 3 trial terminated early — BIOGEN Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta

Phase 3 trial terminated early — AMGEN Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adul

Phase 3 trial terminated early — INCYTE A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Phase 3 trial terminated early — REGENERON Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia

Phase 3 trial terminated early — Medtronic Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventr

Phase 3 trial terminated early — Medtronic Ligasure II: Standard Stapling Versus Ligasure

Phase 3 trial terminated early — AbbVie UNITE Study: Understanding New Interventions With GBM ThErapy

Phase 3 trial terminated early — AbbVie A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endomet

Phase 3 trial terminated early — Merck LARC Forward Contraceptive Counseling at MHCC

Phase 3 trial terminated early — Merck Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian

Phase 3 trial terminated early — Merck Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (

Phase 3 trial terminated early — Merck Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Phase 3 trial terminated early — PFIZER Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic

Phase 3 trial terminated early — PFIZER Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy

Phase 3 trial terminated early — PFIZER Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Para

Phase 3 trial terminated early — PFIZER An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dim

Phase 3 trial terminated early — PFIZER A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheime

Phase 3 trial terminated early — PFIZER A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In

Phase 3 trial terminated early — ABBOTT The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Car

Phase 3 trial terminated early — ABBOTT Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheum

Phase 3 trial terminated early — ABBOTT Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's

Phase 3 trial terminated early — GILEAD B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Phase 3 trial terminated early — GILEAD (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effect

Phase 3 trial terminated early — GILEAD Virtual PrEP: Rendering PrEP Delivery More Efficient

Phase 3 trial terminated early — GILEAD Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropa

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Activist 13D filing — tender offer

OSINT: USAF reports loss of E-4B and three KC-135 tankers in incident

Bond issued at elevated rate 4.9% — credit-stress signal

Bond issued at elevated rate 4.75% — credit-stress signal

Bond issued at elevated rate 4.75% — credit-stress signal

Bond issued at elevated rate 5.3% — credit-stress signal

Bond issued at elevated rate 5.0% — credit-stress signal

Bond issued at elevated rate 5.375% — credit-stress signal

Bond issued at elevated rate 5.65% — credit-stress signal

Bond issued at elevated rate 5.15% — credit-stress signal

Bond issued at elevated rate 5.375% — credit-stress signal

Bond issued at elevated rate 6.219% — credit-stress signal

Bond issued at elevated rate 4.75% — credit-stress signal

Bond issued at elevated rate 5.7% — credit-stress signal

Bond issued at elevated rate 4.9% — credit-stress signal

Bond issued at elevated rate 4.75% — credit-stress signal

Bond issued at elevated rate 4.75% — credit-stress signal

Bond issued at elevated rate 5.0% — credit-stress signal

Bond issued at elevated rate 5.3% — credit-stress signal

Bond issued at elevated rate 5.375% — credit-stress signal

Bond issued at elevated rate 5.65% — credit-stress signal

Bond issued at elevated rate 5.15% — credit-stress signal

Bond issued at elevated rate 6.219% — credit-stress signal

Bond issued at elevated rate 5.375% — credit-stress signal

Bond issued at elevated rate 5.7% — credit-stress signal

Bond issued at elevated rate 4.75% — credit-stress signal

Sanofi search volume spiked +77 pts — unusual interest

KLA CORP search volume spiked +39 pts — unusual interest

Q4-2025: Beat consensus by 10.2% — EPS $0.4 vs $0.3629 estimate

Q1-2026: Missed consensus by 8.4% — EPS $0.8 vs $0.8736 estimate

Q1-2026: Beat consensus by 7.6% — EPS $1.5 vs $1.3943 estimate

Q3-2025: Beat consensus by 5.2% — EPS $1.58 vs $1.5012 estimate

Q4-2026: Missed consensus by 198.0% — EPS $-0.01 vs $0.0102 estimate

Q1-2026: Beat consensus by 207.8% — EPS $0.011 vs $-0.0102 estimate

Q4-2025: Missed consensus by 25.8% — EPS $-0.29 vs $-0.2305 estimate

Q1-2026: Missed consensus by 595.8% — EPS $-0.78 vs $-0.1121 estimate

Q4-2019: Beat consensus by 241.0% — EPS $4.34 vs $1.2726 estimate

Q1-2020: Missed consensus by 88.1% — EPS $0.2 vs $1.6766 estimate

Q3-2024: Beat consensus by 201.9% — EPS $3552.91 vs $1176.8008 estimate

Q4-2024: Missed consensus by 296.3% — EPS $-791.835 vs $403.2991 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.38 vs $0.3392 estimate

Beat consensus by 7.9% — EPS $0.26 vs $0.241 estimate

Q4-2025: Beat consensus by 5.8% — EPS $0.31 vs $0.2929 estimate

Q3-2025: Beat consensus by 10.9% — EPS $0.43 vs $0.3876 estimate

Q2-2025: Missed consensus by 25.7% — EPS $0.25 vs $0.3366 estimate

Q2-2025: Beat consensus by 10.4% — EPS $1.302 vs $1.1797 estimate

Q1-2026: Beat consensus by 24.6% — EPS $1.15 vs $0.9229 estimate

Q3-2025: Missed consensus by 9.6% — EPS $0.93 vs $1.0288 estimate

Beat consensus by 253.0% — EPS $16 vs $4.532 estimate

Missed consensus by 23.7% — EPS $13.2 vs $17.304 estimate

Missed consensus by 51.0% — EPS $0.1 vs $0.204 estimate

Missed consensus by 30.7% — EPS $-0.4 vs $-0.306 estimate

Missed consensus by 61.5% — EPS $-21.7 vs $-13.433 estimate

Missed consensus by 197.6% — EPS $-168.35 vs $-56.56 estimate

Q1-2024: Missed consensus by 47.1% — EPS $-18.2 vs $-12.3725 estimate

Q1-2027: Beat consensus by 5.6% — EPS $0.14 vs $0.1326 estimate

Q1-2026: Beat consensus by 43.1% — EPS $0.26 vs $0.1817 estimate

Beat consensus by 18.1% — EPS $0.66 vs $0.559 estimate

Q4-2025: Missed consensus by 7.5% — EPS $0.61 vs $0.6592 estimate

Q1-2026: Beat consensus by 11.7% — EPS $0.3 vs $0.2686 estimate

Q2-2025: Beat consensus by 13.7% — EPS $0.67 vs $0.5893 estimate

Q3-2025: Beat consensus by 15.8% — EPS $0.61 vs $0.5266 estimate

Q2-2012: Beat consensus by 126.3% — EPS $20 vs $-76.1532 estimate

Q1-2012: Missed consensus by 134.2% — EPS $-180 vs $-76.8468 estimate

Beat consensus by 586.3% — EPS $140 vs $20.4 estimate

Missed consensus by 14.2% — EPS $140 vs $163.2 estimate

Q3-2025: Missed consensus by 929.4% — EPS $-0.21 vs $-0.0204 estimate

Q1-2026: Beat consensus by 34.6% — EPS $-0.04 vs $-0.0612 estimate

Missed consensus by 56.9% — EPS $-0.08 vs $-0.051 estimate

Q4-2025: Missed consensus by 138.1% — EPS $-0.17 vs $-0.0714 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.64 vs $1.4975 estimate

Q2-2025: Missed consensus by 7.6% — EPS $0.91 vs $0.9847 estimate

Q2-2025: Missed consensus by 14.4% — EPS $23.14 vs $27.0246 estimate

Q3-2025: Missed consensus by 161.9% — EPS $-9.96 vs $16.1024 estimate

Q1-2026: Beat consensus by 66.0% — EPS $42.52 vs $25.6166 estimate

Missed consensus by 354.1% — EPS $-28.11406 vs $11.062 estimate

Q1-2026: Beat consensus by 5.2% — EPS $0.22 vs $0.2091 estimate

Q4-2025: Beat consensus by 42.0% — EPS $0.25 vs $0.1761 estimate

Q1-2026: Missed consensus by 113.2% — EPS $-104.41 vs $-48.9668 estimate

Q3-2026: Beat consensus by 30.3% — EPS $524.42805 vs $402.4668 estimate

Q4-2026: Beat consensus by 25.8% — EPS $737.77 vs $586.3999 estimate

Q2-2026: Beat consensus by 183.1% — EPS $437.38079 vs $154.5037 estimate

Q2-2025: Missed consensus by 11.0% — EPS $0.62 vs $0.6963 estimate

Q3-2025: Missed consensus by 19.9% — EPS $0.54 vs $0.6738 estimate

Q1-2026: Beat consensus by 24.4% — EPS $0.85 vs $0.6831 estimate

Q2-2025: Beat consensus by 7.9% — EPS $1.26 vs $1.1675 estimate

Q3-2025: Beat consensus by 10.0% — EPS $1.37 vs $1.2452 estimate

Q2-2019: Beat consensus by 35.1% — EPS $0.93 vs $0.6882 estimate

Q3-2019: Missed consensus by 36.3% — EPS $0.45 vs $0.7066 estimate

Q4-2019: Missed consensus by 11.1% — EPS $0.3 vs $0.3376 estimate

Q1-2020: Missed consensus by 246.7% — EPS $-0.42 vs $0.2863 estimate

Missed consensus by 42.4% — EPS $-318 vs $-223.38 estimate

Beat consensus by 98.8% — EPS $-1.8 vs $-149.94 estimate

Missed consensus by 114.9% — EPS $-4083 vs $-1900.26 estimate

Missed consensus by 322.0% — EPS $-361.6 vs $-85.68 estimate

Missed consensus by 83.8% — EPS $-3 vs $-1.632 estimate

Missed consensus by 191.7% — EPS $-2.38 vs $-0.816 estimate

Beat consensus by 47.2% — EPS $-1.4 vs $-2.652 estimate

Q4-2025: Missed consensus by 50.5% — EPS $0.01 vs $0.0202 estimate

Beat consensus by 8.1% — EPS $0.04 vs $0.037 estimate

Q1-2026: Beat consensus by 65.0% — EPS $0.05 vs $0.0303 estimate

Q1-2026: Missed consensus by 67.0% — EPS $0.01 vs $0.0303 estimate

Q2-2025: Beat consensus by 33.9% — EPS $0.97 vs $0.7242 estimate

Q1-2026: Beat consensus by 27.8% — EPS $1.17 vs $0.9158 estimate

Q3-2025: Beat consensus by 15.5% — EPS $0.99 vs $0.8568 estimate

Q4-2025: Beat consensus by 27.4% — EPS $1.16 vs $0.9104 estimate

Texas Permian Basin: drought conditions detected — potential oil supply impact

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: US S&P 500 Index Slides 5%

Cotton bull 6.3% vs prior close ($75.01 → $79.73)

Platinum volume spike — 2.4× the 20-day average (31 vs 12 avg)

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: US Oil Market Alert Signals Potential Supply Shift

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: US and Iran Seal Agreement at Bürgenstock, Switzerland

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC SILVER speculator at extreme short — contrarian bull signal

OSINT: China Deploys New 155mm Naval Gun, Boosting Firepower Near Taiwan

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Oil -6.69% — significant selloff

Wheat bull 4.3% vs prior close ($596.00 → $621.50)

Platinum bear 4.1% vs prior close ($1,812.10 → $1,738.30)

Gold -1.12% — significant selloff

Oil -1.13% — significant selloff

ETH ETF inflow of $139M — institutional buying

BTC ETF inflow of $1031M — institutional buying

ETH open interest +225.5% — OI surge

BTC open interest +248.9% — OI surge

SOL open interest -62.5% — OI collapse

BTC open interest +67.0% — OI surge

ETH open interest -67.9% — OI collapse

SOL open interest -34.4% — OI collapse

ETH open interest -68.9% — OI collapse

BTC open interest +102.6% — OI surge

SOL open interest -33.1% — OI collapse

SPYx/USDC has $67.6M volume but only $748K liquidity — thin market, slippage risk

ETH open interest -66.8% — OI collapse

BTC open interest -40.7% — OI collapse

SOL open interest -32.3% — OI collapse

OSINT: USAF reports loss of E-4B and three KC-135 tankers in incident

VIX at 18.4 — CAUTION territory

OSINT: US Housing Starts Plunge 15.4% MoM in May, Lowest Since 2020

DXY RSI 71.8 — overbought (crossed above 70)